open access
Male-specific consequences of obesity — functional hypogonadism and fertility disorders
Affiliations- Department of Reproductive Health, Center of Postgraduate Medical Education, Warsaw, Poland
open access
Abstract
Obesity is currently one of the most serious public health problems which affects up to 30-40% of the population, and its prevalence is higher in men than in women. Complications of obesity include atherosclerosis, cardiovascular diseases, and type 2 diabetes mellitus, but it also has a negative impact on the hormonal system and fertility. The hormonal consequences of excess body fat in men are functional hypogonadism, which not only causes clinical symptoms of testosterone deficiency, but is also a risk factor for obesity (a vicious circle mechanism). Reduced fertility in obese men may be a consequence of functional hypogonadotropic hypogonadism (decreased gonadotropins and testosterone secretion, reduced libido, and erectile dysfunction), but other mechanisms associated with excess adipose tissue, like hyperinsulinaemia, hyperleptinaemia, chronic inflammation, and oxidative stress also play an important role. Therefore, in
obese men deterioration of semen parameters (sperm concentration, motility, and morphology) and reduced fertility are observed, also concerning the effectiveness of assisted reproductive techniques. Reducing the mass of adipose tissue causes an increase in testosterone concentrations and has a beneficial effect on semen parameters. Functional hypogonadism in obese men should be diagnosed only after exclusion of organic causes of hypogonadism. Lifestyle changes, including physical exercise and low-caloric diet, and optimization of comorbidities, are still first line of treatment. In some patients, if such treatment is ineffective, pharmacotherapy or bariatric surgery may be considered. Testosterone replacement therapy is contraindicated in obese men with functional hypogonadism, especially in those who desire fertility. Selective oestrogen receptor modulators and aromatase inhibitors improve sperm quality but are not recommended for the treatment of hypogonadism in obese men. GLP-1 analogues appear to be effective and safe in the treatment of low testosterone and infertility in obese men and may be the main method of pharmacotherapy in the future.
Abstract
Obesity is currently one of the most serious public health problems which affects up to 30-40% of the population, and its prevalence is higher in men than in women. Complications of obesity include atherosclerosis, cardiovascular diseases, and type 2 diabetes mellitus, but it also has a negative impact on the hormonal system and fertility. The hormonal consequences of excess body fat in men are functional hypogonadism, which not only causes clinical symptoms of testosterone deficiency, but is also a risk factor for obesity (a vicious circle mechanism). Reduced fertility in obese men may be a consequence of functional hypogonadotropic hypogonadism (decreased gonadotropins and testosterone secretion, reduced libido, and erectile dysfunction), but other mechanisms associated with excess adipose tissue, like hyperinsulinaemia, hyperleptinaemia, chronic inflammation, and oxidative stress also play an important role. Therefore, in
obese men deterioration of semen parameters (sperm concentration, motility, and morphology) and reduced fertility are observed, also concerning the effectiveness of assisted reproductive techniques. Reducing the mass of adipose tissue causes an increase in testosterone concentrations and has a beneficial effect on semen parameters. Functional hypogonadism in obese men should be diagnosed only after exclusion of organic causes of hypogonadism. Lifestyle changes, including physical exercise and low-caloric diet, and optimization of comorbidities, are still first line of treatment. In some patients, if such treatment is ineffective, pharmacotherapy or bariatric surgery may be considered. Testosterone replacement therapy is contraindicated in obese men with functional hypogonadism, especially in those who desire fertility. Selective oestrogen receptor modulators and aromatase inhibitors improve sperm quality but are not recommended for the treatment of hypogonadism in obese men. GLP-1 analogues appear to be effective and safe in the treatment of low testosterone and infertility in obese men and may be the main method of pharmacotherapy in the future.
Keywords
obesity; men; hypogonadism; infertility; bariatric surgery; testosterone replacement therapy; GLP-1 analogues
About this articleTitle
Male-specific consequences of obesity — functional hypogonadism and fertility disorders
Journal
Issue
Article type
Review paper
Pages
480-489
Published online
2023-08-17
Page views
987
Article views/downloads
673
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2023;74(5):480-489.
Keywords
obesity
men
hypogonadism
infertility
bariatric surgery
testosterone replacement therapy
GLP-1 analogues
Authors
Michał Rabijewski
References (73)- World Health Organization. Obesity and overweight, 2018. www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
- Wojtyniak B, Goryński P. Sytuacja zdrowotna ludności Polski i jej uwarunkowania. Narodowy Instytut Zdrowia Publicznego — Państwowy Zakład Higieny, Warszawa 2020.
- Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017; 102(3): 1067–1075.
- Tajar A, Forti G, O'Neill TW, et al. EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010; 95(4): 1810–1818.
- De Lorenzo A, Noce A, Moriconi E, et al. MOSH Syndrome (Male Obesity Secondary Hypogonadism): Clinical Assessment and Possible Therapeutic Approaches. Nutrients. 2018; 10(4).
- Fui MN, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl. 2014; 16(2): 223–231.
- Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity. Med Hypotheses. 1999; 52(1): 49–51.
- Saylor PJ, Smith MR, Saylor PJ, et al. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009; 181(5): 1998–2006; discussion 2007.
- Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, et al. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update. 2017; 23(4): 390–408.
- Sultan S, Patel AG, El-Hassani S, et al. Male Obesity Associated Gonadal Dysfunction and the Role of Bariatric Surgery. Front Endocrinol (Lausanne). 2020; 11: 408.
- Jensterle M, Podbregar A, Goricar K, et al. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019; 8(3): 195–202.
- Narinx N, David K, Walravens J, et al. Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology. Cell Mol Life Sci. 2022; 79(11): 543.
- Goldman AL, Bhasin S, Wu FCW, et al. A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications. Endocr Rev. 2017; 38(4): 302–324.
- Grossmann M. Hypogonadism and male obesity: Focus on unresolved questions. Clin Endocrinol (Oxf). 2018; 89(1): 11–21.
- Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. J Endocrinol. 2014; 220(3): R37–R55.
- Clarke H, Dhillo WS, Jayasena CN. Comprehensive Review on Kisspeptin and Its Role in Reproductive Disorders. Endocrinol Metab (Seoul). 2015; 30(2): 124–141.
- Souteiro P, Belo S, Oliveira SC, et al. AMTCO Group. Insulin resistance and sex hormone-binding globulin are independently correlated with low free testosterone levels in obese males. Andrologia. 2018; 50(7): e13035.
- Haffner SM, Shaten J, Stern MP, et al. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996; 143(9): 889–897.
- Rabijewski M, Papierska L, Zgliczyński W, et al. The incidence of hypogonadotropic hypogonadism in type 2 diabetic men in Polish population. Biomed Res Int. 2013; 2013: 767496.
- Ghaderpour S, Ghiasi R, Heydari H, et al. The relation between obesity, kisspeptin, leptin, and male fertility. Horm Mol Biol Clin Investig. 2021; 43(2): 235–247.
- Harter CJL, Kavanagh GS, Smith JT. The role of kisspeptin neurons in reproduction and metabolism. J Endocrinol. 2018; 238(3): R173–R183.
- Bianchi VE. The Anti-Inflammatory Effects of Testosterone. J Endocr Soc. 2019; 3(1): 91–107.
- Sarchielli E, Comeglio P, Squecco R, et al. Tumor Necrosis Factor-α Impairs Kisspeptin Signaling in Human Gonadotropin-Releasing Hormone Primary Neurons. J Clin Endocrinol Metab. 2017; 102(1): 46–56.
- Fernandez CJ, Chacko EC, Pappachan JM. Male Obesity-related Secondary Hypogonadism - Pathophysiology, Clinical Implications and Management. Eur Endocrinol. 2019; 15(2): 83–90.
- Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007; 30(2): 234–238.
- Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010; 33(6): 1186–1192.
- Mohr BA, Bhasin S, Link CL, et al. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol. 2006; 155(3): 443–452.
- Brand JS, Rovers MM, Yeap BuB, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PLoS One. 2014; 9(7): e100409.
- Antonio L, Wu FCW, O'Neill TW, et al. European Male Ageing Study Study Group. Low Free Testosterone Is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone. J Clin Endocrinol Metab. 2016; 101(7): 2647–2657.
- Nielsen TL, Hagen C, Wraae K, et al. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. J Clin Endocrinol Metab. 2007; 92(7): 2696–2705.
- Di Vincenzo A, Busetto L, Vettor R, et al. Obesity, Male Reproductive Function and Bariatric Surgery. Front Endocrinol (Lausanne). 2018; 9: 769.
- Wu FCW, Tajar A, Beynon JM, et al. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010; 363(2): 123–135.
- Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003; 139(3): 161–168.
- Araujo AB, Johannes CB, Feldman HA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med. 2000; 30(4): 328–338.
- Rabijewski M, Papierska L, Kozakowski J, et al. The high prevalence of testosterone deficiency in population of Polish men over 65 years with erectile dysfunctions. Aging Male. 2012; 15(4): 258–262.
- Rabijewski M, Papierska L, Kuczerowski R, et al. Hormonal determinants of erectile dysfunction and lower urinary tract symptoms in middle-aged and elderly men with prediabetes. Aging Male. 2015; 18(4): 256–264.
- Pizzol D, Smith L, Fontana L, et al. Associations between body mass index, waist circumference and erectile dysfunction: a systematic review and META-analysis. Rev Endocr Metab Disord. 2020; 21(4): 657–666.
- Wang JM, Li ZF, Yang WX, et al. Follicle-stimulating hormone signaling in Sertoli cells: a licence to the early stages of spermatogenesis. Reprod Biol Endocrinol. 2022; 20(1): 97.
- Li X, Li H, Jia L, et al. Oestrogen action and male fertility: experimental and clinical findings. Cell Mol Life Sci. 2015; 72(20): 3915–3930.
- Carrageta DF, Oliveira PF, Alves MG, et al. Obesity and male hypogonadism: Tales of a vicious cycle. Obes Rev. 2019; 20(8): 1148–1158.
- Leisegang K, Sengupta P, Agarwal A, et al. Obesity and male infertility: Mechanisms and management. Andrologia. 2021; 53(1): e13617.
- LA Padula D, Zavaglia L, Hamad T, et al. Leptin effects: focusing on the relationship between obesity and male infertility. Minerva Endocrinol (Torino). 2022 [Epub ahead of print].
- Paul C, Melton DW, Saunders PTK. Do heat stress and deficits in DNA repair pathways have a negative impact on male fertility? Mol Hum Reprod. 2008; 14(1): 1–8.
- Panner Selvam MK, Ambar RF, Agarwal A, et al. Etiologies of sperm DNA damage and its impact on male infertility. Andrologia. 2021; 53(1): e13706.
- Alahmar AT, Singh R, Palani A, et al. Coenzyme Q10, oxidative stress, and male infertility: A review. Clin Exp Reprod Med. 2021; 48(2): 97–104.
- Sengupta P, Dutta S, Krajewska-Kulak E. The Disappearing Sperms: Analysis of Reports Published Between 1980 and 2015. Am J Mens Health. 2017; 11(4): 1279–1304.
- Chavarro JE, Toth TL, Wright DL, et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril. 2010; 93(7): 2222–2231.
- Sermondade N, Faure C, Fezeu L, et al. BMI in relation to sperm count: an updated systematic review and collaborative meta-analysis. Hum Reprod Update. 2013; 19(3): 221–231.
- Salas-Huetos A, Maghsoumi-Norouzabad L, James ER, et al. Male adiposity, sperm parameters and reproductive hormones: An updated systematic review and collaborative meta-analysis. Obes Rev. 2021; 22(1): e13082.
- Wang S, Sun J, Wang J, et al. Does obesity based on body mass index affect semen quality?-A meta-analysis and systematic review from the general population rather than the infertile population. Andrologia. 2021; 53(7): e14099.
- Ramlau-Hansen CH, Thulstrup AM, Nohr EA, et al. Subfecundity in overweight and obese couples. Hum Reprod. 2007; 22(6): 1634–1637.
- Bibi R, Jahan S, Afsar T, et al. The influence of paternal overweight on sperm chromatin integrity, fertilization rate and pregnancy outcome among males attending fertility clinic for IVF/ICSI treatment. BMC Pregnancy Childbirth. 2022; 22(1): 620.
- Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology. Andrology. 2020; 8(5): 970–987.
- Camacho EM, Huhtaniemi IT, O'Neill TW, et al. EMAS Group. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013; 168(3): 445–455.
- Corona G, Rastrelli G, Morelli A, et al. Treatment of Functional Hypogonadism Besides Pharmacological Substitution. World J Mens Health. 2020; 38(3): 256–270.
- Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013; 168(6): 829–843.
- Emami MR, Safabakhsh M, Khorshidi M, et al. Effect of bariatric surgery on endogenous sex hormones and sex hormone-binding globulin levels: a systematic review and meta-analysis. Surg Obes Relat Dis. 2021; 17(9): 1621–1636.
- Xu J, Wu Q, Zhang Y, et al. Effect of Bariatric Surgery on Male Sexual Function: A Meta-Analysis and Systematic Review. Sex Med. 2019; 7(3): 270–281.
- Lee Y, Dang JT, Switzer N, et al. Impact of Bariatric Surgery on Male Sex Hormones and Sperm Quality: a Systematic Review and Meta-Analysis. Obes Surg. 2019; 29(1): 334–346.
- Gao Z, Liang Y, Yang S, et al. Bariatric Surgery Does Not Improve Semen Quality: Evidence from a Meta-analysis. Obes Surg. 2022; 32(4): 1341–1350.
- Guo B, Li JJ, Ma YL, et al. Efficacy and safety of letrozole or anastrozole in the treatment of male infertility with low testosterone-estradiol ratio: A meta-analysis and systematic review. Andrology. 2022; 10(5): 894–909.
- Cannarella R, Condorelli RA, Mongioì LM, et al. Effects of the selective estrogen receptor modulators for the treatment of male infertility: a systematic review and meta-analysis. Expert Opin Pharmacother. 2019; 20(12): 1517–1525.
- Di Giulio F, Castellini C, Tienforti D, et al. Erectile dysfunction in hyperuricemia: A prevalence meta-analysis and meta-regression study. Andrology. 2022; 10(1): 72–81.
- Jayasena CN, Anderson RA, Llahana S, et al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf). 2022; 96(2): 200–219.
- Burnett-Bowie SAM, Roupenian KC, Dere ME, et al. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2009; 70(1): 116–123.
- Burnett-Bowie SAM, McKay EA, Lee H, et al. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009; 94(12): 4785–4792.
- Birzniece V, Sata A, Sutanto S, et al. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. J Clin Endocrinol Metab. 2010; 95(12): 5443–5448.
- Cai X, Tian Ye, Wu T, et al. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl. 2014; 16(1): 146–152.
- Mangolim AS, Brito Ld, Nunes-Nogueira VD. Effectiveness of testosterone replacement in men with obesity: a systematic review and meta-analysis. Eur J Endocrinol. 2021; 186(1): 123–135.
- Jensterle M, Podbregar A, Goricar K, et al. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019; 8(3): 195–202.
- Izzi-Engbeaya C, Jones S, Crustna Y, et al. Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men. J Clin Endocrinol Metab. 2020; 105(4): 1119–1125.
- La Vignera S, Condorelli RA, Calogero AE, et al. Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results. J Clin Med. 2023; 12(2).
- Andersen E, Juhl CR, Kjøller ET, et al. Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. Hum Reprod. 2022; 37(7): 1414–1422.
